The study was funded by the the National Cancer Institute.

Presented in six separate abstracts of last week Heart Rhythm 2011 in San Francisco, contain data groundbreaking findings from the company EFFICAS I post – market clinical trial to fundamentally new insights into the relationship between catheter tip-to – tissue contact force and early pulmonary shed vein line reconduction. – ‘EFFICAS I represents the most rigorous and detailed investigation ever of the role of contact force during catheter ablation performed and the results are truly remarkable,’said Karl-Heinz Kuck, Asklepios Klinik St. Hamburg, Germany. Multi-center first time we have clearly a direct correlation between low contact force and post-operative PVI line reconduction shown three month follow-up.

We look forward to continuing our leadership position in this area to firmly position contact – force control as a standard therapy for the treatment of cardiac arrhythmias. .. – New Contact force and force-time-integral mapping and visualization techniques can help electrophysiologists potential areas of PVI line reconduction help to long-term AF recurrence6, 7. 2006, Endosense has long been indisputable for the construction of scientific evidence supporting the value of contact-force sensing and the TactiCath, and today we are very proud to be a leader depth in the industry with a clinical program is unrivaled in its breadth, and committed contribution to clinical practice, said Eric Le Royer, president and chief executive officer of Endosense.The Phase 1 trial was a randomized, controlled trial in the United States of 120 healthy volunteers. The primary endpoints is safety and immunogenicity determined by neutralization serum and plasma components.

The underlying technology is for NB – 1008 is NanoBio NanoStatTM platform which engaged a nano – emulsion, which is a proprietary a proprietary manufacturing process. The nanoemulsion is unique capable permeating the nasal mucosa, which it able vaccinal antigen to immunological presenting cells be loaded. These cells are will wear the antigen to portions of the body, which trigger an immune response, 1008 lymph nodes, thymus and spleen. Nanobiotechnology has various stages of preclinical development for several other nanoemulsion-adjuvanted vaccines, including hepatitis B, pandemic, pneumococcal, anthrax and smallpox.

Other articles from category "allergy":

Random articles